In brief
- The act was signed June 4; its general clause contemplates August 12 conditionally and the pilot has separate funding-dependent activation.
- It provides for up to five research sites, with operation conditional on federal approval; it does not establish active sites or current licences.
- The text includes benefit sharing in specified circumstances and for licensees, not an identical duty for every person.
HB26-1325, signed June 4, 2026, establishes a framework for ibogaine research and possible natural-medicine rules. It does not mean ibogaine is available at centers or that access outside trials is operating. Its general clause contemplates August 12 conditionally, while pilot provisions have additional funding-dependent activation.
What the law specifically authorizes
The text, titled simply Natural Medicine, authorizes BHA to select up to five sites and assist with federal IND applications. Each pilot site’s operation is expressly conditional on federal approval. Specified pilot provisions activate on receipt of $150,000 in contributions or equivalent in-kind value before January 1, 2028, with notice to the revisor of statutes. Further operating-cost funding conditions apply. Contributions, notices and selected sites were not checked here; permitted funding sources are not money actually received.
The act permits rules on ibogaine administration, manufacturing and use, and substance-specific fees. It does not replace rulemaking or verification of licences and authorizations. This review read the signed text and official summary, not current licence inventories or rules; the earlier claim of no licences today is therefore not retained as current fact.
Benefit sharing and facilitator protections
The act requires benefit-sharing plans for specified pilot applicants or licensees, including sourcing documentation in the pilot. The summary includes licensed cultivation, manufacturing, dispensing and administration, with Indigenous-community consultation; this is not an undifferentiated obligation on everyone or proof of implemented agreements. Ibogaine derives from Tabernanthe iboga, a Central African shrub linked to the Bwiti ritual practices of Gabon, and the international rise in its use has reignited the debate over resource extraction and the recognition of origin peoples. You can read more about the plant and its pharmacology in our guide on iboga and ibogaine.
The law also adjusts advisory-board experience requirements. Facilitator protection is limited to money damages in civil malpractice actions for physical or psychological injuries arising from services performed or supervised. It does not apply to administrative proceedings and excludes intentional misconduct, gross negligence or deviation from the recognized standard of care.
What this implies
For policy comparison, we covered Texas, which is funding conventional clinical trials, without ranking states. Creating a legal pathway, obtaining funding, securing federal approval and opening sites are separate facts. None follows automatically from the others, and recruitment or results timelines were not verified here.
The pilot’s purpose is to investigate safety and efficacy, not establish that treatment is safe. A written framework also does not demonstrate each clinic’s actual compliance. Unchecked figures about thousands of travelers or blanket descriptions of foreign clinics without oversight are not retained here. Inferring availability would require checking implementation and specific authorizations, rather than extrapolating state text to general federal permission.
Source
- Colorado General Assembly. HB26-1325 “Natural Medicine”: legislative history and official summary. Colorado General Assembly, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
